Serum M2BPGi level is a novel predictive biomarker for the responses to pegylated interferon-α treatment in HBeAg-positive chronic hepatitis B patients

Ming-Yu Zhu, Pei-Zhan Chen, Jing Li, De-Min Yu, Dao Huang, Xue-Juan Zhu, Yue Han, Jie Chen, Wei Huang, Yong-Yan Chen, Qi-Ming Gong, Jie-Hong Jiang, Dong-Hua Zhang, Yan Zhang, Ji-Ming Zhang, Xin-Xin Zhang
  • Journal of Medical Virology, January 2018, Wiley
  • DOI: 10.1002/jmv.25010

The authors haven't yet claimed this publication.

Read Publication

http://dx.doi.org/10.1002/jmv.25010

In partnership with: